MedTrace Logo

Rosuvastatin in Visceral Adiposity

NCT01068626 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2015-08-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate whether 6 months treatment with the cholesterol-lowering drug rosuvastatin may reduce visceral fat tissue in obese middle aged men.

Conditions

  • Abdominal Obesity

Interventions

DRUG

Rosuvastatin

10 mg once daily

DRUG

Placebo for rosuvastatin

once daily

Sponsors & Collaborators

  • Sahlgrenska University Hospital

    collaborator OTHER

  • Göteborg University

    lead OTHER

Principal Investigators

  • John-Olov Jansson, Prof · Department of Endocrinology, University of Gothenburg

  • Claes Ohlsson, Professor · Department of Clinical Pharmocology, University of Gothenburg

  • Anna Nilsson, MD, PhD · Department of Endocrinology, University of Gothenburg

  • Kristjan Karason, MD, PhD · Department of Molecular and Clinical Medicine at University of Gothenburg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2008-10-31
Completion
2008-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01068626 on ClinicalTrials.gov